Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Véronique Trillet Lenoir"'
Autor:
Yutaro Kaneko, Ryo Hatano, Naoto Hirota, Nicolas Isambert, Véronique Trillet-Lenoir, Benoit You, Jérôme Alexandre, Gérard Zalcman, Fanny Valleix, Thomas Podoll, Yoshimi Umezawa, Seiichi Takao, Satoshi Iwata, Osamu Hosono, Tetsuo Taguchi, Taketo Yamada, Nam H. Dang, Kei Ohnuma, Eric Angevin, Chikao Morimoto
Publikováno v:
Biomarker Research, Vol 9, Iss 1, Pp 1-13 (2021)
Abstract Background The phase I trial of the humanized anti-CD26 monoclonal antibody YS110 for CD26-expressing tumors was conducted recently. The present study identifies a potential prognostic biomarker for CD26-targeted therapy based on the phase I
Externí odkaz:
https://doaj.org/article/869532e7d9924a45b065a8c40a83cd05
Autor:
Xavier Pivot, Gilles Romieu, Pierre Fumoleau, Maria Rios, Hervé Bonnefoi, Thomas Bachelot, Patrick Soulié, Christelle Jouannaud, Hugues Bourgeois, Thierry Petit, Isabelle Tennevet, David Assouline, Marie-Christine Mathieu, Jean-Philippe Jacquin, Sandrine Lavau-Denes, Ariane Darut-Jouve, Jean-Marc Ferrero, Carole Tarpin, Christelle Lévy, Valérie Delecroix, Véronique Trillet-Lenoir, Oana Cojocarasu, Jérôme Meunier, Jean-Yves Pierga, Cécile Agostini, Pierre Kerbrat, Céline Faure-Mercier, Hélène Blanché, Mourad Sahbatou, Anne Boland, Delphine Bacq, Céline Besse, Fabien Calvo, Alexia Renaud, Jean-François Deleuze, Iris Pauporté, Gilles Thomas, David G. Cox
Publikováno v:
npj Breast Cancer, Vol 3, Iss 1, Pp 1-5 (2017)
Genetics: heredity does not explain HER2 expression A large gene-finding study failed to identify any hereditary factors linked to HER2 expression among women with breast cancer. A team in France led by Xavier Pivot from the University Hospital Cente
Externí odkaz:
https://doaj.org/article/7754f161934e43488fc3e34446964363
Autor:
Bastien Collomb, Amélie Dubromel, Anne Gaëlle Caffin, Chloé Herledan, Virginie Larbre, Amandine Baudouin, Ariane Cerutti, Laurence Couturier, Magali Maire, Lionel Karlin, Delphine Maucort-Boulch, Laure Huot, Stéphane Dalle, Emmanuel Bachy, Hervé Ghesquieres, Gilles Salles, Sébastien Couraud, Benoit You, Gilles Freyer, Véronique Trillet-Lenoir, Florence Ranchon, Catherine Rioufol
Publikováno v:
Cancers, Vol 14, Iss 660, p 660 (2022)
Cancers; Volume 14; Issue 3; Pages: 660
Cancers; Volume 14; Issue 3; Pages: 660
Background In previous studies, patient-reported outcomes (PROs) have been shown to improve survival in cancer patients. The aim of the present study was to assess symptoms potentially related to adverse events experienced by cancer outpatients treat
Autor:
Fanny Valleix, Tetsuo Taguchi, Benoit You, Yutaro Kaneko, Thomas Podoll, Naoto Hirota, Nicolas Isambert, Kei Ohnuma, Ryo Hatano, Gérard Zalcman, Nam H. Dang, Eric Angevin, Véronique Trillet-Lenoir, Seiichi Takao, Yoshimi Umezawa, Taketo Yamada, Chikao Morimoto, Osamu Hosono, Satoshi Iwata, Jérôme Alexandre
Publikováno v:
Biomarker Research
Biomarker Research, Vol 9, Iss 1, Pp 1-13 (2021)
Biomarker Research, Vol 9, Iss 1, Pp 1-13 (2021)
Background The phase I trial of the humanized anti-CD26 monoclonal antibody YS110 for CD26-expressing tumors was conducted recently. The present study identifies a potential prognostic biomarker for CD26-targeted therapy based on the phase I data. Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36ce65814344ffa433e56209cace7b82
https://doi.org/10.21203/rs.3.rs-126614/v1
https://doi.org/10.21203/rs.3.rs-126614/v1
Autor:
Sophie Tartas, Hassan Errihani, Hanan Raiss, Julien Péron, Véronique Trillet-Lenoir, Gilles Freyer
Publikováno v:
Clinical Breast Cancer. 18:e263-e266
Autor:
Michel Tod, Diane Augu-Denechere, Sophie Tartas, Jonathan Lopez, Juliette Fontaine, Gilles Freyer, Denis Maillet, Benoit You, Véronique Trillet-Lenoir, Nathalie Bonnin, Alicja Puszkiel, Jérôme Guitton, Olivier Colomban, Léa Payen, P. Rousset, Julien Péron
Publikováno v:
Cancer Research. 80:CT148-CT148
Objectives: Defining the optimal doses & dosing schedules of combined targeted drugs is a challenge. Blocking both the PI3K-AKT-mTor and RAS-RAF-ERK pathways is a rationale therapeutic strategy in solid tumors. However, the phase 1 trials of everolim
Autor:
Florence Ranchon, C. Alloux, E. Kiouris, Gilles Freyer, Catherine Rioufol, M. G. Guédat, C. Gourc, P.‐J. Souquet, N. Vantard, Véronique Trillet-Lenoir, S. He, Gilles Salles, V. Schwiertz, N. Gauthier, Benoit You
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 40:196-203
Summary What is known and objectives In cancer care, clinical pharmacists contribute to improving prevention and management of drug-related problems (DRPs). The 3-year EPICC study (Evaluation of Pharmaceutical Intervention in Cancer Care) aimed to co
Autor:
Maria Rios, Alexia Renaud, Valérie Delecroix, Oana Cojocarasu, Céline Besse, Fabien Calvo, Mourad Sahbatou, Véronique Trillet-Lenoir, Ariane Darut-Jouve, Sandrine Lavau-Denes, Patrick Soulié, Hélène Blanché, Hervé Bonnefoi, Marie-Christine Mathieu, Céline Faure-Mercier, David G. Cox, Jean-Yves Pierga, Christelle Jouannaud, Thierry Petit, Jean-Marc Ferrero, Pierre Kerbrat, Christelle Levy, Carole Tarpin, Thomas Bachelot, Jérôme Meunier, Anne Boland, David Assouline, Gilles Romieu, Jean-François Deleuze, Cécile Agostini, Gilles Thomas, Isabelle Tennevet, Delphine Bacq, Jean-Philippe Jacquin, Iris Pauporté, Pierre Fumoleau, Xavier Pivot, Hugues Bourgeois
Publikováno v:
NPJ Breast Cancer
npj Breast Cancer, Vol 3, Iss 1, Pp 1-5 (2017)
npj Breast Cancer, Vol 3, Iss 1, Pp 1-5 (2017)
Human epidermal growth factor receptor 2-positive breast cancer is a subtype of interest regarding its outcome and the impressive impact of human epidermal growth factor receptor 2 targeted therapy. Constitutional variants may be involved in the aeti
Autor:
N. Vantard, Véronique Trillet-Lenoir, V. Schwiertz, C. Alloux, N. Gauthier, Benoit You, Florence Ranchon, S. He, Catherine Rioufol, E. Kiouris, Gilles Freyer, M.‐P. Gustin, C. Gourc-Berthod, M. G. Guédat, L. Sarfati
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 40:55-62
Summary What is known and objective Medication errors (ME) in oncology are known to cause serious iatrogenic complications. However, MEs still occur at each step in the anticancer chemotherapy process, particularly when injections are prepared in the
Autor:
Carole Tarpin, Sophie Paget-Bailly, Xavier Pivot, David Assouline, Maria Rios, Isabelle Tennevet, Gilles Romieu, Jean-Marc Ferrero, Céline Faure-Mercier, Pierre Fumoleau, Jean-François Deleuze, David G. Cox, Hélène Blanché, Marie-Christine Mathieu, Thierry Petit, Christelle Jouannaud, Hugues Bourgeois, Oana Cojocarasu, Thomas Bachelot, Elsa Curtit, Jérôme Meunier, Ariane Darut-Jouve, Delphine Bacq, Jean-Yves Pierga, Sandrine Lavau-Denes, Iris Pauporté, Valérie Delecroix, Christelle Levy, Patrick Soulié, Pierre Kerbrat, Véronique Trillet-Lenoir, Anne Boland, Hervé Bonnefoi, Mourad Sahbatou, Gilles Thomas, Jean-Philippe Jacquin, Julie Henriques, Céline Besse
Publikováno v:
Breast Cancer Research
Breast Cancer Research, BioMed Central, 2016, 19 (1), pp.98. ⟨10.1186/s13058-017-0888-4⟩
Breast Cancer Research, BioMed Central, 2016, 19 (1), pp.98. 〈10.1186/s13058-017-0888-4〉
Breast Cancer Research, 2016, 19 (1), pp.98. ⟨10.1186/s13058-017-0888-4⟩
Breast Cancer Research : BCR
Breast Cancer Research, BioMed Central, 2016, 19 (1), pp.98. ⟨10.1186/s13058-017-0888-4⟩
Breast Cancer Research, BioMed Central, 2016, 19 (1), pp.98. 〈10.1186/s13058-017-0888-4〉
Breast Cancer Research, 2016, 19 (1), pp.98. ⟨10.1186/s13058-017-0888-4⟩
Breast Cancer Research : BCR
Background Genome-wide association studies (GWAS) have to date identified 94 genetic variants (single nucleotide polymorphisms (SNPs)) associated with risk of developing breast cancer. A score based on the combined effect of the 94 risk alleles can b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eb052dcc905000343748771611cce2b
https://www.hal.inserm.fr/inserm-01577637
https://www.hal.inserm.fr/inserm-01577637